-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China’s medical aesthetics industry started late, but with the rise of the “face value economy”, it has developed rapidly.
According to Frost & Sullivan, the scale of China’s compliant medical aesthetics market has grown from 52.
1 billion in 2014 to 142.
7 billion in 2019, with an average annual The compound growth rate reached 22.
33%, and it is predicted to continue to increase to 222 billion in 2022
.
In the face of the huge medical aesthetics market, many companies in the industry are making cross-border deployments
.
Especially in the context of the normalization of centralized procurement and the general trend of drug price reduction, many pharmaceutical companies are looking for a path of transformation due to obvious performance pressure.
Medical beauty has become a new track for many pharmaceutical companies to enter
.
Flush data shows that as of November 15, there were 51 A-share medical beauty concept stocks, involving listed companies in the fields of real estate, textiles, and electronics
.
Among them, the number of listed companies from the pharmaceutical and biological industry is as high as 31, accounting for more than 60%
.
Not long ago, Xingkerong Pharmaceutical, a Hong Kong-listed company, announced that it will invest 88.
5 million yuan in cooperation with Beijing Nuukangda to develop polycaprolactone microsphere facial fillers for injection (collectively referred to as "girl needles" in the industry) and its materials and layout.
Medical beauty industry
.
It is reported that from the announcement to the close of November 15th, the cumulative increase of the stock has exceeded 100%
.
It is understood that the "girl needle" is a non-surgical medical beauty product, which is favored by many consumers at home and abroad, and the market scale is expanding
.
Data show that the scale of China's non-surgical medical aesthetics market will increase from 54.
5 billion yuan in 2020 to 98 billion yuan in 2022, with a compound annual growth rate of 34.
1%
.
Xingkerong Pharmaceutical will develop polycaprolactone microsphere facial fillers for injection and its materials against the domestically marketed "girl needle" Ellansé, which has been officially put into commercial sales in August this year
.
According to the data, Xingkerong Pharmaceutical mainly focuses on the distribution of imported blood products and anti-infective drugs and other prescription drugs.
Based on the national marketing and promotion network, it cooperates with many domestic and foreign pharmaceutical companies to provide comprehensive Marketing, promotion and channel management services
.
Under the strict supervision of the blood products industry, Xingkerong Pharmaceutical still occupies a place in the domestic market
.
Statistics show that in 2020, the market share of Xingkerong Pharmaceutical's human albumin injection has reached the second place in the country
.
In the first half of 2021, due to the substantial increase in the company's human albumin injection supply and sales volume, the company's operating income increased to approximately 847 million yuan, a year-on-year increase of 33.
1%
.
Among them, the income of human albumin injection is about 805 million yuan, accounting for 95.
1%; the income of antibiotics is 41.
610 million yuan, accounting for 4.
9%
.
It is reported that, in order to meet the company's future deployment of medical aesthetics and other fields, as well as the huge demand for the cold chain of medicine in the storage and transportation of blood products and biological products, Xingkerong Pharmaceutical is actively deploying
.
According to the company's information, it has now completed the establishment of a cold chain storage facility with an area of 15,000 square meters, and is about to build a cold chain storage facility of 25,000 square meters and a R&D base of 47,000 square meters.
The development of the field provides strong support
.
It is worth mentioning that the industry pointed out that the transformation of the medical aesthetics market for enterprises still requires a process and tests the technology, brand strength and customer resources of the enterprise
.
In addition, industry supervision is continuously tightening
.
In June this year, the National Health Commission and other eight departments issued the "Special Rectification Work Plan for Combating Illegal Medical Beauty Services", which is scheduled to be launched nationwide from June to December 2021 to crack down on illegal medical beauty services.
Illegal medical beauty activities will promote the further standardization of the medical beauty industry
.
According to Frost & Sullivan, the scale of China’s compliant medical aesthetics market has grown from 52.
1 billion in 2014 to 142.
7 billion in 2019, with an average annual The compound growth rate reached 22.
33%, and it is predicted to continue to increase to 222 billion in 2022
.
In the face of the huge medical aesthetics market, many companies in the industry are making cross-border deployments
.
Especially in the context of the normalization of centralized procurement and the general trend of drug price reduction, many pharmaceutical companies are looking for a path of transformation due to obvious performance pressure.
Medical beauty has become a new track for many pharmaceutical companies to enter
.
Flush data shows that as of November 15, there were 51 A-share medical beauty concept stocks, involving listed companies in the fields of real estate, textiles, and electronics
.
Among them, the number of listed companies from the pharmaceutical and biological industry is as high as 31, accounting for more than 60%
.
Not long ago, Xingkerong Pharmaceutical, a Hong Kong-listed company, announced that it will invest 88.
5 million yuan in cooperation with Beijing Nuukangda to develop polycaprolactone microsphere facial fillers for injection (collectively referred to as "girl needles" in the industry) and its materials and layout.
Medical beauty industry
.
It is reported that from the announcement to the close of November 15th, the cumulative increase of the stock has exceeded 100%
.
It is understood that the "girl needle" is a non-surgical medical beauty product, which is favored by many consumers at home and abroad, and the market scale is expanding
.
Data show that the scale of China's non-surgical medical aesthetics market will increase from 54.
5 billion yuan in 2020 to 98 billion yuan in 2022, with a compound annual growth rate of 34.
1%
.
Xingkerong Pharmaceutical will develop polycaprolactone microsphere facial fillers for injection and its materials against the domestically marketed "girl needle" Ellansé, which has been officially put into commercial sales in August this year
.
According to the data, Xingkerong Pharmaceutical mainly focuses on the distribution of imported blood products and anti-infective drugs and other prescription drugs.
Based on the national marketing and promotion network, it cooperates with many domestic and foreign pharmaceutical companies to provide comprehensive Marketing, promotion and channel management services
.
Under the strict supervision of the blood products industry, Xingkerong Pharmaceutical still occupies a place in the domestic market
.
Statistics show that in 2020, the market share of Xingkerong Pharmaceutical's human albumin injection has reached the second place in the country
.
In the first half of 2021, due to the substantial increase in the company's human albumin injection supply and sales volume, the company's operating income increased to approximately 847 million yuan, a year-on-year increase of 33.
1%
.
Among them, the income of human albumin injection is about 805 million yuan, accounting for 95.
1%; the income of antibiotics is 41.
610 million yuan, accounting for 4.
9%
.
It is reported that, in order to meet the company's future deployment of medical aesthetics and other fields, as well as the huge demand for the cold chain of medicine in the storage and transportation of blood products and biological products, Xingkerong Pharmaceutical is actively deploying
.
According to the company's information, it has now completed the establishment of a cold chain storage facility with an area of 15,000 square meters, and is about to build a cold chain storage facility of 25,000 square meters and a R&D base of 47,000 square meters.
The development of the field provides strong support
.
It is worth mentioning that the industry pointed out that the transformation of the medical aesthetics market for enterprises still requires a process and tests the technology, brand strength and customer resources of the enterprise
.
In addition, industry supervision is continuously tightening
.
In June this year, the National Health Commission and other eight departments issued the "Special Rectification Work Plan for Combating Illegal Medical Beauty Services", which is scheduled to be launched nationwide from June to December 2021 to crack down on illegal medical beauty services.
Illegal medical beauty activities will promote the further standardization of the medical beauty industry
.
